ASCO 2018 News

home / news-network / asco-2018-news

EP. 1: OncLive News Network On Location: In Chicago Friday, June 1

EP. 2: OncLive News Network On Location: In Chicago Saturday, June 2

EP. 3: OncLive News Network On Location: In Chicago Sunday, June 3

EP. 4: OncLive News Network On Location: In Chicago Monday, June 4

Practice Changes for Use of Immunotherapy in NSCLC

EP. 5: Practice Changes for Use of Immunotherapy in NSCLC

ASCO 2018: Dr. Borghaei Highlights Immunotherapy Findings in Lung Cancer

EP. 6: ASCO 2018: Dr. Borghaei Highlights Immunotherapy Findings in Lung Cancer

ASCO 2018: Dr. Esteva Highlights CDK4/6 Inhibitors and More in Breast Cancer

EP. 7: ASCO 2018: Dr. Esteva Highlights CDK4/6 Inhibitors and More in Breast Cancer

ASCO 2018: Dr. Burris Highlights TAILORx and More in Breast Cancer

EP. 8: ASCO 2018: Dr. Burris Highlights TAILORx and More in Breast Cancer

ASCO 2018: Dr. Lonial Highlights CAR T-Cell Therapy and More in Myeloma

EP. 9: ASCO 2018: Dr. Lonial Highlights CAR T-Cell Therapy and More in Myeloma

ASCO 2018: Dr. Weber Highlights Exciting Abstracts in Melanoma

EP. 10: ASCO 2018: Dr. Weber Highlights Exciting Abstracts in Melanoma

ASCO 2018: Dr. Coleman Shares Insight on Ongoing Research in Ovarian Cancer

EP. 11: ASCO 2018: Dr. Coleman Shares Insight on Ongoing Research in Ovarian Cancer

ASCO 2018: Dr. Bekaii-Saab Highlights Pancreatic Cancer Abstracts

EP. 12: ASCO 2018: Dr. Bekaii-Saab Highlights Pancreatic Cancer Abstracts

ASCO 2018: Dr. Birrer on Practice-Changing Ovarian Cancer Studies

EP. 13: ASCO 2018: Dr. Birrer on Practice-Changing Ovarian Cancer Studies

ASCO 2018: Dr. Westin Sheds Light on PARP Inhibitor Abstracts in Ovarian Cancer

EP. 14: ASCO 2018: Dr. Westin Sheds Light on PARP Inhibitor Abstracts in Ovarian Cancer

KEYNOTE Trial Data: Pembrolizumab's Role in NSCLC

EP. 15: KEYNOTE Trial Data: Pembrolizumab's Role in NSCLC

Actual Use of Pembrolizumab and Chemotherapy in NSCLC

EP. 16: Actual Use of Pembrolizumab and Chemotherapy in NSCLC

CheckMate-227: Testing Ipilimumab/Nivolumab in NSCLC

EP. 17: CheckMate-227: Testing Ipilimumab/Nivolumab in NSCLC

IMPower150: Implications for the Treatment of NSCLC

EP. 18: IMPower150: Implications for the Treatment of NSCLC

Important Data in the Squamous NSCLC Population

EP. 19: Important Data in the Squamous NSCLC Population

Impact of Data on the Real-Life Treatment of NSCLC

EP. 20: Impact of Data on the Real-Life Treatment of NSCLC

Tumor Mutational Burden in NSCLC: Should it be Routine?

EP. 21: Tumor Mutational Burden in NSCLC: Should it be Routine?

Optimizing Immunotherapy in the NSCLC Treatment Paradigm

EP. 22: Optimizing Immunotherapy in the NSCLC Treatment Paradigm

Using Immunotherapy Beyond Progression in NSCLC

EP. 23: Using Immunotherapy Beyond Progression in NSCLC

Practice Changes for Use of Immunotherapy in NSCLC: Q&A

EP. 24: Practice Changes for Use of Immunotherapy in NSCLC: Q&A

Latest Conference Coverage

Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD

Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma

Serial ctDNA Testing Could Improve Risk Stratification in High-Risk MIBC

Adjuvant Nivolumab Provides Sustained DFS Benefit, Favors OS in Muscle-Invasive Urothelial Cancer

View More Latest Conference Coverage

Editorial Board

CancerNetwork.com

OncNursingNews.com

TargetedOnc.com

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.